Every day millions of people are taking medicines which are not effective for their specific disease. Some widely used drugs are often truly beneficial only on a small percentage of the population.
Personalised medicine aims to develop and prescribe medications that are active on the one-patient, focusing on the single person instead of a large study group.
This new frontier of medicine is taking into account genetic and environmental factors among the others, opening new perspectives for cancer and rare diseases as well as widely diffused disorders.
Join us for an evening of talks on this innovative field, followed by a panel discussion and a networking session with the speakers!
Tim Guilliams - Founder & CEO at Healx
Mathew Garnett - Wellcome Trust Sanger Institute
Vincent Plagnol - VP Computational Biology at Inivata
Jean Abraham - Dept. of Oncology, University of Cambridge
Cath Brooksbank - Head of Training at EMBL-EBI
Monday, March 06th 2017
18:00 – 21:00 (GMT)
Department of Chemistry, University of Cambridge